The U.S. FDA granted Gtx Medical BV a breakthrough device designation for its implantable Go-2 Targeted Epidural Spinal Stimulation (TESS) system. The device enabled patients who had sustained traumatic spinal cord injuries to regain voluntary control over previously paralyzed muscles and walk again four or more years after paralysis, according to a study previously published in Nature.

A long-term clinical trial comparing minimally invasive cryoablation to surgery to treat early stage kidney cancer patients has found that the former offers comparable rates of survival and fewer complications. Johns Hopkins researchers published the 10-year survival data for 134 patients in the June 9, 2020, issue of Radiology.

Researchers at New York-based Feinstein Institutes for Medical Research, the research arm of Northwell Health, showed that anodal block can be used for directional vagus nerve stimulation (VNS) in a new paper in Scientific Reports.

Brisbane, Calif.-based Caredx Inc., which is aiming to transplant patient outcomes, saw the presentation of a host of data at the recent American Transplant Congress annual meeting.

Hesperos Inc.'s Human-on-a-Chip in vitro system demonstrated two types of responses of the immune system in a study conducted with Hoffman-La Roche Pharmaceuticals and the University of Central Florida.

Medical science continues to define the relative risks of progressively smaller patient subsets across the disease spectrum, but this is particularly true of late in connection with aortic stenosis (AS).

Exact Sciences Corp., of Madison, Wis., detailed three studies of the Oncotype Dx Breast Recurrence Score test during the virtual 2020 American Society of Clinical Oncology Annual Meeting.

Investigators are working to develop electrogenetic devices that use remote-controlled electrical stimulation to elicit specific behaviors in engineered cells.

LONDON – A vast new body of genomics research has identified thousands of rare genetic variants that are predicted to cause loss of function in protein coding genes, providing novel in vivo models of human gene inactivation.

Variants in the APOE gene are the strongest genetic risk factor for developing Alzheimer’s disease (AD). Now, researchers at Rockefeller University have demonstrated that APOE variants also affected the risk of progression and metastasis as well as the response to immunotherapy, in melanoma.